The Claim
Increased activation of the orbitofrontal cortex during liraglutide treatment, independent of weight loss, may reflect a counter-regulatory neural response that contributes to the plateauing of weight loss commonly observed with anti-obesity medications.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When people take liraglutide for weight loss, their brain's 'decision-making' area might become more active as a way to push back against further weight loss — which could be why the pounds stop dropping after a while.
See the scientific wording
The increase in orbitofrontal cortex activation during liraglutide treatment, when adjusted for weight loss, may represent a counter-regulatory brain response that contributes to the eventual plateauing of weight loss observed with anti-obesity medications.
What the research says
1 studyThe study shows that when people take liraglutide, their brain’s reward area becomes more active in response to food after accounting for weight loss, which might explain why weight loss slows down over time.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.